|
1
|
Chen VE, Gillespie EF, Zakeri K, Murphy
JD, Yashar CM, Lu S and Einck JP: Pathologic response after
neoadjuvant chemotherapy predicts locoregional control in patients
with triple negative breast cancer. Adv Radiat Oncol. 2:105–109.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Santana-Davila R and Perez EA: Treatment
options for patients with triple-negative breast cancer. J Hematol
Oncol. 3:422010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Verkman AS, Anderson MO and Papadopoulos
MC: Aquaporins: Important but elusive drug targets. Nat Rev Drug
Discov. 13:259–277. 2014. View
Article : Google Scholar : PubMed/NCBI
|
|
4
|
Lee SJ, Chae YS, Kim JG, Kim WW, Jung JH,
Park HY, Jeong JY, Park JY, Jung HJ and Kwon TH: AQP5 expression
predicts survival in patients with early breast cancer. Ann Surg
Oncol. 21:375–383. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Verkman AS: Aquaporins in clinical
medicine. Annu Rev Med. 63:303–316. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ishibashi K, Tanaka Y and Morishita Y: The
role of mammalian superaquaporins inside the cell. Biochim Biophys
Acta. 1840:1507–1512. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Li Y, Wang W, Jiang T and Yang B:
Aquaporins in urinary system. Adv Exp Med Biol. 969:131–148. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Liu S, Zhang S, Jiang H, Yang Y and Jiang
Y: Co-expression of AQP3 and AQP5 in esophageal squamous cell
carcinoma correlates with aggressive tumor progression and poor
prognosis. Med Oncol. 30:6362013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Filippidis AS, Carozza RB and Rekate HL:
Aquaporins in brain edema and neuropathological conditions. Int J
Mol Sci. 18:pii: E55. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ikarashi N, Kon R, Kaneko M, Mizukami N,
Kusunoki Y and Sugiyama K: Relationship between aging-related skin
dryness and aquaporins. Int J Mol Sci. 18:pii: E1559. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Esteva-Font C, Jin BJ and Verkman AS:
Aquaporin-1 gene deletion reduces breast tumor growth and lung
metastasis in tumor-producing MMTV-PyVT mice. FASEB J.
28:1446–1453. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kang BW, Kim JG, Lee SJ, Chae YS and Jeong
JY, Yoon GS, Park SY, Kim HJ, Park JS, Choi GS and Jeong JY:
Expression of aquaporin-1, aquaporin-3, and aquaporin-5 correlates
with nodal metastasis in colon cancer. Oncology. 88:369–376. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Chen J, Wang T, Zhou YC, Gao F, Zhang ZH,
Xu H, Wang SL and Shen LZ: Aquaporin 3 promotes
epithelial-mesenchymal transition in gastric cancer. J Exp Clin
Cancer Res. 33:382014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Guo X, Sun T, Yang M, Li Z, Li Z and Gao
Y: Prognostic value of combined aquaporin 3 and aquaporin 5
overexpression in hepatocellular carcinoma. Biomed Res Int.
2013:2065252013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Direito I, Paulino J, Vigia E, Brito MA
and Soveral G: Differential expression of aquaporin-3 and
aquaporin-5 in pancreatic ductal adenocarcinoma. J Surg Oncol.
115:980–996. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Ribatti D, Ranieri G, Annese T and Nico B:
Aquaporins in cancer. Biochimica et Biophysica Acta.
1840:1550–1553. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wang J, Feng L, Zhu Z, Zheng M, Wang D,
Chen Z and Sun H: Aquaporins as diagnostic and therapeutic targets
in cancer: How far we are? J Transl Med. 13:962015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Gatto F, Feelders RA, van der Pas R, Kros
JM, Waaijers M, Sprij-Mooij D, Neggers SJ, van der Lelij AJ, Minuto
F, Lamberts SW, et al: Immunoreactivity score using an anti-sst2A
receptor monoclonal antibody strongly predicts the biochemical
response to adjuvant treatment with somatostatin analogs in
acromegaly. J Clin Endocrinol Metab. 98:E66–E71. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Rampurwala M, Wisinski KB and Regan RO:
Role of the androgen receptor in triple-negative breast cancer.
Clin Adv Hematol Oncol. 14:186–193. 2016.PubMed/NCBI
|
|
20
|
Satooka H and Hara-Chikuma M: Aquaporin-3
controls breast cancer cell migration by regulating hydrogen
peroxide transport and its downstream cell signaling. Mol Cell
Biol. 36:1206–1218. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Shen L, Zhu Z, Huang Y, Shu Y, Sun M, Xu
H, Zhang G, Guo R, Wei W and Wu W: Expression profile of multiple
aquaporins in human gastric carcinoma and its clinical
significance. Biomed Pharmacother. 64:313–318. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Huang Y, Zhu Z, Sun M, Wang J, Guo R, Shen
L and Wu W: Critical role of aquaporin-3 in the human epidermal
growth factor-induced migration and proliferation in the human
gastric adenocarcinoma cells. Cancer Biol Ther. 9:1000–1007. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Papadopoulos MC and Saadoun S: Key roles
of aquaporins in tumor biology. Biochim Biophys Acta.
1848:2576–2583. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Xia H, Ma YF, Yu CH, Li YJ, Tang J, Li JB,
Zhao YN and Liu Y: Aquaporin 3 knockdown suppresses tumour growth
and angiogenesis in experimental non-small cell lung cancer. Exp
Physiol. 99:974–984. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Shi Z, Zhang T, Luo L, Zhao H, Cheng J,
Xiang J and Zhao C: Aquaporins in human breast cancer:
Identification and involvement in carcinogenesis of breast cancer.
J Surg Oncol. 106:267–272. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Kang S, Chae YS, Lee SJ, Kang BW, Kim JG,
Kim WW, Jung JH, Park HY, Jeong JH, Jeong JY and Park JY: Aquaporin
3 expression predicts survival in patients with HER2-positive early
breast cancer. Anticancer Res. 35:2775–2782. 2015.PubMed/NCBI
|
|
27
|
Yang J, Yan C, Zheng W and Chen X:
Proliferation inhibition of cisplatin and aquaporin 5 expression in
human ovarian cancer cell CAOV3. Arch Gynecol Obstet. 285:239–245.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Ishimoto S, Wada K, Usami Y, Tanaka N,
Aikawa T, Okura M, Nakajima A, Kogo M and Kamisaki Y: Differential
expression of aquaporin 5 and aquaporin 3 in squamous cell
carcinoma and adenoid cystic carcinoma. Int J Oncol. 41:67–75.
2012.PubMed/NCBI
|
|
29
|
Schlotter CM, Tietze L, Vogt U, Heinsen CV
and Hahn A: Ki67 and lymphocytes in the pretherapeutic core biopsy
of primary invasive breast cancer: Positive markers of therapy
response prediction and superior survival. Horm Mol Biol Clin
Investig. 32:pii:/j/hmbci. 2017.PubMed/NCBI
|
|
30
|
Kowarik MC, Soltys J and Bennett JL: The
treatment of neuromyelitis optica. J Neuroophthalmol. 34:70–82.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Soveral G and Casini A: Aquaporin
modulators: A patent review (2010–2015). Expert Opin Ther Pat.
27:49–62. 2017. View Article : Google Scholar : PubMed/NCBI
|
